Stay updated on Fruquintinib in Metastatic Colorectal Cancer Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.

Latest updates to the Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check16 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed descriptions of a clinical trial for metastatic colorectal cancer and the addition of a new version number. The name of the study director has also been updated.SummaryDifference26%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated to reflect new timelines and methodologies related to the analysis of adverse events and efficacy of fruquintinib, including changes in the definitions of treatment-emergent adverse events (TEAEs) and the duration of study drug administration. Additionally, the revision number has been updated to v2.14.4.SummaryDifference14%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference0.6%
Stay in the know with updates to Fruquintinib in Metastatic Colorectal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib in Metastatic Colorectal Cancer Clinical Trial page.